A new study has tested the hypothesis that patients with serum antibodies against recombinant myelin oligodendrocyte glycoprotein (MOG) and purified myelin basic protein (MBP) are at an increased ...
Tocilizumab and rituximab reduce relapse rates and disability progression in NMOSD, with tocilizumab provides extra benefits in MOGAD.
Hosted on MSN2mon
Dementia and Sleep; Functional Neurologic Disorder and Long COVID; Autism-Gut Link?(Neuron) Sex and ethnicity predicted a relapsing course in myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD); treatment shortly after onset lowers the risk of the second event.
6mon
Medpage Today on MSNBrain Clock Disparities; How Morphine Relieves Pain; Tolebrutinib and MS Disability(Alzheimer's and Dementia) Early treatment of a first acute myelin oligodendrocyte glycoprotein antibody-associated disease ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results